Clene Inc. CLNN
4.25 USD +0.05 (+1.31%)
Nov 12, 2026, 12:00 PM EST
4.05 Day range 4.25
3.10 52-week range 10.36
- YTD
- -27.60%
- 1 year
- -54.84%
News
benzinga.com Clene Q3 EPS $0.05 Beats $(0.45) Estimate, Sales $56.000K Miss $74.000K Estimate Clene (NASDAQ:CLNN) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.45) by 111.11 percent. This is a 105.88 percent increase over losses of $(0.85) per…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
benzinga.com Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 3M shares rose 4.4% premarket after expanding its Amazon data-center deal, including a $521.4M stock warrant; other stocks saw sharp moves.
benzinga.com HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
benzinga.com Datavault AI Receives Initial Purchase Order For $100M Of Its $QEST Tokenization Services Nathaniel Bradley, Co-Founder and CEO of Datavault AI Inc. (NASDAQ:DVLT), presents today, Tuesday, September 15, at 3:30 PM ET at the Lotte New York Palace Hotel in New York City.Datavault AI Inc.…
benzinga.com Clene Prices Registered Direct Offering Of 1,219,513 Shares At $3.28/Shr To Existing Shareholders With Total Gross Proceeds Of $4M Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million…- benzinga.com Clene Q1 EPS $(0.69) Misses $(0.66) Estimate, Sales $15.000K Miss $35.064K Estimate Clene (NASDAQ:CLNN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.66) by 4.55 percent. This is a 666.67 percent decrease over losses of $(0.09) per…
benzinga.com HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
benzinga.com Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed technical indicators in focus.
benzinga.com Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels highlight momentum and key price zones.- benzinga.com Clene Announces FDA Approves Propose Data To Be Capable for Submission, Review Of New Drug Application For Pathway To Treat Amyotrophic Lateral Sclerosis Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Clene Q4 EPS $(0.88) Misses $(0.56) Estimate, Sales $77.000K Beat $49.000K Estimate Clene (NASDAQ:CLNN) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.56) by 57.99 percent. This is a 47.31 percent increase over losses of $(1.67) per…- benzinga.com Clene Announces FDA Grants In-Person Type C Meeting In Q1 2026 As New Analyses Support NfL Reduction And CNM‑Au8 Biomarker Findings Linked To Lower ALS Mortality Risk The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are…
- benzinga.com Clene Commences $28M Offering Of Securities Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Clene Completes FDA-Recommended Biomarker Analyses For CNM-Au8 In Patients With Amyotrophic Lateral Sclerosis; Data Shows Reductions In Neurofilament Light, Glial Fibrillary Acidic Protein Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on…
benzinga.com Clene To Update Investors On CNM-Au8 ALS Program In December 3 Webcast At 8:30am ET Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Clene Q3 EPS $(0.85) Misses $(0.58) Estimate, Sales $15.000K Miss $55.143K Estimate Clene (NASDAQ:CLNN) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.58) by 46.55 percent. This is a 30.33 percent increase over losses of $(1.22) per…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $23 price target.- benzinga.com Benchmark Maintains Buy on Clene, Lowers Price Target to $31 Benchmark analyst Bruce D. Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $33 to $31.
- benzinga.com Clene Inc Announces New Preclinical Data Showing That Its Lead Candidate, CNM-Au8, Improved Cellular Health In A Dopaminergic Neuron Model Of Parkinson's Disease Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize…
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Canaccord Genuity Maintains Buy on Clene, Lowers Price Target to $48 Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $83 to $48.
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com Clene Q2 EPS $(0.78) Misses $(0.47) Estimate, Sales $27.000K Miss $52.833K Estimate Clene (NASDAQ:CLNN) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.47) by 64.9 percent. This is a 26.42 percent increase over losses of $(1.06) per…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Benchmark Maintains Buy on Clene, Lowers Price Target to $33 Benchmark analyst Bruce Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $84 to $33.
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com Clene Q1 EPS $(0.09) Beats $(0.79) Estimate, Sales $81.00K Beat $61.75K Estimate Clene (NASDAQ:CLNN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.79) by 88.61 percent. This is a 94.8 percent increase over losses of $(1.73) per…
- benzinga.com Jones Trading Initiates Coverage On Clene with Buy Rating, Announces Price Target of $30 Jones Trading analyst Justin Walsh initiates coverage on Clene (NASDAQ:CLNN) with a Buy rating and announces Price Target of $30.
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
- benzinga.com D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
- benzinga.com Clene Announced New Evidence From A Cross-Regimen, Post Hoc Analysis Of Long-Term Survival In HEALEY ALS Platform Trial Participants Clene, Inc. (NASDAQ:CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including…